PMID- 23094314
OWN - NLM
STAT- MEDLINE
DCOM- 20121106
LR  - 20141120
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 90
IP  - 3
DP  - 2012 Sep
TI  - Preliminary study of the efficacy and tolerability of combination therapy with 
      calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of 
      stable plaque psoriasis.
PG  - 140-4
AB  - Calcipotriene ointment is widely used in the topical treatment of psoriasis, with 
      tacrolimus ointment as an effective alternative in controlling stable plaque 
      psoriasis. The efficacy of the combination of both products on stable plaque 
      psoriasis has not been assessed in the literature consulted. We evaluated the 
      efficacy of calcipotriene ointment 0.005% applied twice daily, tacrolimus 
      ointment 0.1% applied twice daily, or a morning application of calcipotriene and 
      an evening application of tacrolimus in 27 participants with stable plaque 
      psoriasis over an 8-week treatment period. The mean reduction in the sum of the 
      scores between baseline and week 8 was significant (P = .001) for calcipotriene 
      alone (39.5%), tacrolimus alone (38.2%), and the combination of calcipotriene and 
      tacrolimus (60.7%). Combination therapy was statistically more effective than 
      tacrolimus alone (P = .043) but not statistically superior to calcipotriene alone 
      (P=.056). Most adverse events (AEs) were related to skin irritation and pruritus; 
      however, no AEs were evident in participants given the combination therapy.
FAU - Tirado-Sanchez, Andres
AU  - Tirado-Sanchez A
AD  - Department of Dermatology, Hospital General de Mexico, Mexico City. 
      atsdermahgm@gmail.com
FAU - Ponce-Olivera, Rosa Maria
AU  - Ponce-Olivera RM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ointments)
RN  - 143NQ3779B (calcipotriene)
RN  - FXC9231JVH (Calcitriol)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Calcitriol/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Ointments
MH  - Pilot Projects
MH  - Psoriasis/*drug therapy/pathology
MH  - Tacrolimus/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/10/26 06:00
MHDA- 2012/11/07 06:00
CRDT- 2012/10/26 06:00
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2012/11/07 06:00 [medline]
PST - ppublish
SO  - Cutis. 2012 Sep;90(3):140-4.